

Special Issue

Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness

Message from the Guest Editor

Inhibitory antibodies targeting the PD-1/PD-L1 pathway are now widely used in different types of cancers such as melanoma, lung, head and neck, kidney, and some hematological malignancies. The medical advances made possible by these new drugs are undeniable, however, a significant number of patients do not benefit from this therapy due to the intrinsic or acquired resistance of their tumor to PD-(L)1 inhibition.

The objective of this Special Issue entitled “Combination Therapy Strategies for Cancer PD-1/PD-L1 Pathway Blockade Awareness” is to highlight original research related to the identification of synergistic therapeutic combinations with anti-PD-(L)1 that take into account the tumor immune context. Studies that describe strategies to sensitize “cold” (immunogenic drugs, vaccination, PRR agonists) and “immuno-excluded” tumors (modulators of fibrosis, angiogenesis, etc.), or a strategy to bypass acquired resistance in previously sensitive tumors are particularly appreciated.

Guest Editor

Dr. Emeric Limagne

Cancer Biology Transfer Platform, Department of Pathology and Tumor Biology, Anticancer Center Georges-François Leclerc, Dijon, France
“Cancer and adaptive immune response” team, INSERM Research Center LNC-UMR1231, University of Bourgogne-Franche-Comté, Dijon, France

Deadline for manuscript submissions

closed (30 June 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/44486

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)